Scarica l'app Stockscreener
1.08
0.93%
0.01
Precedente Chiudi:
$1.07
Aprire:
$1.09
Volume 24 ore:
123.00K
Relative Volume:
0.54
Capitalizzazione di mercato:
$65.42M
Reddito:
-
Utile/perdita netta:
$-64.86M
Rapporto P/E:
-0.9643
EPS:
-1.12
Flusso di cassa netto:
$-55.66M
1 W Prestazione:
+0.00%
1M Prestazione:
+0.00%
6M Prestazione:
-62.04%
1 anno Prestazione:
-68.97%
Intervallo 1D:
$1.04
$1.115
Intervallo di 1 settimana:
$0.9999
$1.1552
Portata 52W:
$0.8551
$3.92
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Nome
Acumen Pharmaceuticals Inc
Settore
Industria
Telefono
925-368-8508
Indirizzo
427 PARK ST., CHARLOTTESVILLE
Confronta ABOS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
1.08 | 65.42M | 0 | -64.86M | -55.66M | -1.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-26 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-07-20 | Ripresa | BofA Securities | Buy |
| 2023-05-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-07-15 | Iniziato | BTIG Research | Buy |
| 2022-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2022-01-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-07-26 | Iniziato | BofA Securities | Neutral |
| 2021-07-26 | Iniziato | Credit Suisse | Outperform |
| 2021-07-26 | Iniziato | Stifel | Buy |
| 2021-07-26 | Iniziato | UBS | Buy |
Mostra tutto
Acumen Pharmaceuticals Inc Borsa (ABOS) Ultime notizie
Halozyme to Report First Quarter 2025 Financial and Operating Results - Yahoo Finance
JPMorgan Chase & Co. Has $1.61 Million Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
ABOS stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa
ABOS stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting - The Manila Times
Game-Changing Trial Screening Method: Acumen Advances Alzheimer's Research with pTau217 Innovation - Stock Titan
Charles Schwab Investment Management Inc. Acquires 18,004 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors - The Manila Times
What is HC Wainwright’s Forecast for ABOS FY2029 Earnings? - Defense World
FY2029 Earnings Forecast for ABOS Issued By HC Wainwright - The AM Reporter
UBS Group Lowers Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target to $4.00 - Defense World
Acumen Pharmaceuticals outlines ALTITUDE AD Phase 2 plans and late 2026 data timeline - MSN
HC Wainwright Has Lowered Expectations for Acumen Pharmaceuticals (NASDAQ:ABOS) Stock Price - Defense World
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Cut to $11.00 by Analysts at HC Wainwright - The AM Reporter
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2024 Earnings Call Transcript - Insider Monkey
Acumen Pharmaceuticals’ Earnings Call: Progress Amid Challenges - TipRanks
Bank of America Securities Sticks to Its Buy Rating for Acumen Pharmaceuticals (ABOS) - The Globe and Mail
Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
UBS Cuts Price Target on Acumen Pharmaceuticals to $4 From $6, Keeps Buy Rating - MarketScreener
Acumen Pharmaceuticals Inc (ABOS) Q4 2024 Earnings Call Highlights: Strong Financial Position ... By GuruFocus - Investing.com Canada
Acumen Pharmaceuticals Advances Alzheimer’s Treatment Efforts - TipRanks
Earnings call transcript: Acumen Pharmaceuticals Q4 2024 focuses on Alzheimer’s innovations - Investing.com
Acumen Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights - The Manila Times
Acumen's $231M War Chest Powers Breakthrough Alzheimer's Drug Development - Stock Titan
Earnings Scheduled For March 27, 2025 - Benzinga
Acumen Pharmaceuticals completes Phase 2 trial enrollment By Investing.com - Investing.com South Africa
Preview: Acumen Pharmaceuticals's Earnings - Benzinga
Acumen Enrollment In Phase 2 ALTITUDE-AD Trial Of Sabirnetug For Early Alzheimer's - Nasdaq
Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease - The Manila Times
Acumen Pharmaceuticals completes Phase 2 trial enrollment - Investing.com
Acumen Pharmaceuticals Completes Enrollment Of Altitude-Ad, A Phase 2 Clinical Trial Of Sabirnetug (Acu193) In Early Alzheimer'S Disease - Marketscreener.com
Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease - TradingView
Breakthrough Alzheimer's Treatment Advances: Phase 2 Trial Fills Ahead of Schedule - Stock Titan
Acumen Pharmaceuticals Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Acumen Pharmaceuticals (ABOS) to Release Earnings on Thursday - The AM Reporter
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025 - The Manila Times
Acumen Pharmaceuticals To Report Fourth Quarter And Year-End 2024 Financial Results On March 27, 2025 - MarketScreener
Acumen Pharmaceuticals to Reveal Full Year Performance: Key Updates on Alzheimer's Treatment Progress - StockTitan
Acumen reports positive results for Alzheimer’s drug sabirnetug By Investing.com - Investing.com South Africa
Central Nervous System (CNS) Biomarkers Market Report Analysis - openPR
Acumen Pharma Reports Positive Topline Data For Sabirnetug From Phase 1 Study - Nasdaq
Acumen reports positive results for Alzheimer’s drug sabirnetug - Investing.com
Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers - The Manila Times
Breakthrough in Alzheimer's Treatment: Acumen's New Injectable Drug Shows Promise in Phase 1 - StockTitan
Chlorinated Isopropane Market Set for 4.9% CAGR Growth, Hitting USD 496.0 Million by 2035 | Fact.MR Report - GlobeNewswire
Chlorinated Isopropane Market Set for 4.9% CAGR Growth, Hitting USD 496.0 Million by 2035 | Fact.MR Report - GlobeNewswire Inc.
Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer’s - Yahoo Finance
Acumen Pharmaceuticals at UBS Virtual CNS Day: Alzheimer’s Treatment Focus - Investing.com UK
Acumen Pharmaceuticals (ABOS) Projected to Post Earnings on Tuesday - Defense World
Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting - The Manila Times
Acumen Pharmaceuticals Inc Azioni (ABOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Acumen Pharmaceuticals Inc Azioni (ABOS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Zuga Matt | CFO & Chief Business Officer |
Jan 21 '25 |
Sale |
1.60 |
4,364 |
6,986 |
260,646 |
| OConnell Daniel Joseph | Chief Executive Officer |
Jan 21 '25 |
Sale |
1.59 |
12,619 |
20,102 |
667,488 |
| Meisner Derek M | Chief Legal Officer & Corp Sec |
Jan 21 '25 |
Sale |
1.59 |
3,418 |
5,435 |
161,127 |
| Barton Russell | Chief Operating Officer |
Jan 21 '25 |
Sale |
1.61 |
2,914 |
4,692 |
136,117 |
| Siemers Eric | Chief Medical Officer |
Jan 21 '25 |
Sale |
1.59 |
3,219 |
5,118 |
170,298 |
0.47%
2.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):